- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.05. | Alvotech - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
| 11.05. | Alvotech shares rise as FDA completes Reykjavik facility inspection | 4 | Seeking Alpha | ||
| 11.05. | Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility | 249 | GlobeNewswire (Europe) | - Company remains on track for BLA resubmissions in the second quarter REYKJAVIK, Iceland, May 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing... ► Artikel lesen | |
| 07.05. | Alvotech im ersten Quartal 2026: Umsatzrückgang, aber EBITDA steigt dank verbessertem Ertragsmix | 18 | Investing.com Deutsch | ||
| ALVOTECH SDR Aktie jetzt für 0€ handeln | |||||
| 07.05. | Alvotech Q1 2026 slides: revenue dips 20%, EBITDA rises on mix shift | 9 | Investing.com | ||
| 07.05. | Alvotech verfehlt Q1-Prognose: Aktie bricht nach enttäuschenden Zahlen ein | 8 | Investing.com Deutsch | ||
| 06.05. | Alvotech S.A.: Alvotech Q1 2026 Financial Results | 226 | GlobeNewswire (Europe) | Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights A supplemental long-form earnings release providing additional operational details and business update for Q1 2026... ► Artikel lesen | |
| 04.05. | Alvotech - 6-K, Report of foreign issuer | 12 | SEC Filings | ||
| 30.04. | Alvotech Announces a Change in its Executive Team | 1.254 | GlobeNewswire (Europe) | REYKJAVIK, ICELAND (April 30, 2026) - Alvotech (NASDAQ: ALVO, the "Company"), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide... ► Artikel lesen | |
| 24.04. | Alvotech to Report Financial Results for the First Quarter of 2026 | 17 | GlobeNewswire (USA) | ||
| 31.03. | Alvotech Publishes 2025 Annual Report | 20 | GlobeNewswire (USA) | ||
| 31.03. | Alvotech files Annual Report with the SEC | 7 | GlobeNewswire (USA) | ||
| 31.03. | Alvotech - 20-F, Annual and transition report of foreign private issuers | 6 | SEC Filings | ||
| 24.03. | UBS cuts Alvotech stock price target on delayed biosimilar launches | 9 | Investing.com | ||
| 24.03. | UBS senkt Kursziel für Alvotech wegen verzögerter Biosimilar-Markteinführungen | 41 | Investing.com Deutsch | ||
| 23.03. | Barclays lowers Alvotech stock price target to $4 on approval timing | 8 | Investing.com | ||
| 23.03. | Barclays senkt Kursziel für Alvotech auf 4 US-Dollar wegen Zulassungsverzögerungen | 15 | Investing.com Deutsch | ||
| 19.03. | Alvotech outlines 2026 revenue target of $650M-$700M while expanding global biosimilar launches | 12 | Seeking Alpha | ||
| 19.03. | Alvotech Q4 2025 slides: 21% revenue growth amid FDA hurdles | 11 | Investing.com | ||
| 19.03. | Alvotech - 6-K, Report of foreign issuer | 6 | SEC Filings |
1 2 3 4 5 Weiter >>
87 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| LINEAGE CELL THERAPEUTICS | 1,062 | -6,84 % | Regenerative Medizin im Aufbruch: NurExone Biologic, Regenxbio und Lineage Cell Therapeutics setzen auf unterschiedliche Zukunftstechnologien | ||
| DARWIN AG | 6,400 | 0,00 % | DARWIN AG: Moderates Umsatzwachstum 2026 erwartet | Nach Darstellung der Analysten Cosmin Filker und Matthias Greiffenberger von GBC hat die DARWIN AG im Geschäftsjahr 2025 den Umsatz deutlich auf 54,3 Mio. Euro gesteigert, beim EBITDA aber rote Zahlen... ► Artikel lesen | |
| LYTIX BIOPHARMA | 0,986 | +4,23 % | LYTIX BIOPHARMA ASA: Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances | ||
| IMMUNOVANT | 34,160 | +0,09 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,650 | -0,07 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,620 | 0,00 % | Tango Therapeutics Shares Fall 17% | ||
| QIAGEN | 30,095 | 0,00 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 80,61 | 0,00 % | Kymera presents KT-621 atopic dermatitis trial data at conferences | ||
| SUMMIT THERAPEUTICS | 17,475 | +0,03 % | Bernstein downgrades Summit Therapeutics stock rating on trial concerns | ||
| PRAXIS PRECISION MEDICINES | 350,56 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,010 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines | Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,110 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| NUVALENT | 101,24 | 0,00 % | Bernstein startet Coverage für Nuvalent mit "Outperform"-Rating und hohem Kursziel | ||
| ERASCA | 11,600 | -0,04 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| EVOTEC | 5,080 | 0,00 % | Shortseller-Positionen aktuell: u.a. Evotec, FMC, Gerresheimer, Hypoport, Nagarro, Nordex, Suss MicroTec | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen |
Das Unternehmen ALVOTECH SDR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,785 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALVOTECH SDR finden Sie auf Wallstreet Online.